XETRA - Delayed Quote EUR

CureVac N.V. (5CV.DE)

3.6000

+0.0400

+(1.12%)

At close: May 23 at 5:35:40 PM GMT+2

Earnings Beat: CureVac N.V. (NASDAQ:CVAC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

The analysts might have been a bit too bullish on CureVac N.V. ( NASDAQ:CVAC ), given that the company fell short of...

Simply Wall St. yesterday

CVAC
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial Application filed in Europe with decision expected ...

ACCESS Newswire 4 days ago

CVAC
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendments to specific patent claims A hearing on infringement ...

ACCESS Newswire 9 days ago

CVAC
May 2025's Promising Penny Stocks To Consider

The United States market has shown positive momentum, climbing 3.9% in the last week and up 12% over the past year, with earnings expected to grow by 14% annually. For investors looking beyond established giants, penny stocks—often representing smaller or newer companies—can provide intriguing opportunities. Despite being a somewhat outdated term, these stocks continue to attract interest for their potential value and growth; this article highlights three such stocks that combine financial...

Simply Wall St. 11 days ago

NIO

NIOIF

SANA
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.

Zacks last month

PFE

MRNA

CVAC
CureVac Among 3 Promising Penny Stocks To Watch

The market has climbed by 5.8% over the past week, and is up 4.8% over the past year, with earnings expected to grow by 14% per annum in the coming years. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when built on solid financials. We'll explore several penny stocks that stand out for their financial strength and potential for long-term success, providing investors with a chance to...

Simply Wall St. last month

RES

CVAC

NIO
Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz

The major averages were sharply lower near noon, curtailing some of yesterday’s sharp gains after President Donald Trump announced a 90-day pause on some of his “reciprocal” tariffs, despite announcing an increase on the cumulative tariff rate on Chinese imports. Despite the temporary relief from the tariff suspension, market sentiment remains cautious. Looking to commodities, gold prices are up significantly, approaching the $3,200 threshold. Oil prices, meanwhile, have sharply dropped after se

TipRanks last month

AMZN

AAPL

FSM
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience

CureVac NV (CVAC) reports a robust financial position with a significant licensing agreement with GSK, despite challenges in revenue and ongoing litigation costs.

GuruFocus.com last month

CVAC
Q4 2024 CureVac NV Earnings Call

Q4 2024 CureVac NV Earnings Call

Thomson Reuters StreetEvents last month

CVAC
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout ...

ACCESS Newswire last month

CVAC
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide ...

ACCESS Newswire last month

CVAC
FDA clears CureVac’s IND application for Phase I lung cancer trial

The treatment of subjects is expected to commence in the second half of this year.

Clinical Trials Arena last month

CVAC
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer Proprietary Epitopes: CVHNLC encodes novel tumor epitopes identified through proprietary ...

ACCESS Newswire last month

CVAC
Is CureVac (CVAC) the Best German Stock to Buy According to Hedge Funds?

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where CureVac (NASDAQ:CVAC) stands against other best German stocks to buy according to hedge funds. Germany’s economy is facing continued weakness. According to a report published by Roland […]

Insider Monkey last month

CVAC
Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz

The major indexes were sharply lower near noon as investors react to the release of key inflation data and recent trade policy developments. The Federal Reserve’s key inflation measure, the core personal consumption expenditures price index, showed a 0.4% increase for the month of February, putting the 12-month inflation rate at a hotter-than-expected 2.8%. Looking to commodities, gold prices are fractionally higher, continuing their rally and bringing the record price to above $3,100. Meanwhile

TipRanks last month

AGX

LULU

ORCL
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP 3 708 668 B1 is scheduled for July 1, 2025, before ...

ACCESS Newswire last month

CVAC
CureVac N.V.'s (NASDAQ:CVAC) largest shareholders are individual investors with 38% ownership, private equity firms own 31%

Key Insights Significant control over CureVac by individual investors implies that the general public has more power to...

Simply Wall St. 2 months ago

CVAC
Is CureVac N.V. (CVAC) the Best Get Rich Fast Stock to Buy Now?

We recently compiled a list of the 12 Best Get Rich Fast Stocks To Buy Now. In this article, we are going to take a look at where CureVac N.V. (NASDAQ:CVAC) stands against the other get rich fast stocks. Investing in penny stocks—typically defined as shares trading below $5—can be alluring due to their potential for […]

Insider Monkey 3 months ago

CVAC
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators

CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of the broadest intellectual property portfolios in ...

ACCESS Newswire 3 months ago

CVAC
Discovering Giftify And 2 Other US Penny Stocks With Promising Potential

As U.S. markets show resilience with rising stocks and dipping yields, investors are increasingly exploring diverse opportunities to capitalize on potential growth. Penny stocks, a term that might seem outdated, continue to offer intriguing possibilities for those willing to look beyond the big names. These often smaller or newer companies can present a compelling mix of affordability and growth potential when backed by strong financials, making them an attractive option for discerning...

Simply Wall St. 3 months ago

CVAC

GIFT

Performance Overview

Return	5CV.DE	S&P 500 (^GSPC)
YTD	+21.38%	-1.34%
1-Year	-2.65%	+10.16%
3-Year	-80.22%	+46.03%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CureVac N.V. (5CV.DE)

Earnings Beat: CureVac N.V. (NASDAQ:CVAC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

May 2025's Promising Penny Stocks To Consider

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

CureVac Among 3 Promising Penny Stocks To Watch

Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz

CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience

Q4 2024 CureVac NV Earnings Call

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

FDA clears CureVac’s IND application for Phase I lung cancer trial

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Is CureVac (CVAC) the Best German Stock to Buy According to Hedge Funds?

Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

CureVac N.V.'s (NASDAQ:CVAC) largest shareholders are individual investors with 38% ownership, private equity firms own 31%

Is CureVac N.V. (CVAC) the Best Get Rich Fast Stock to Buy Now?

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators

Discovering Giftify And 2 Other US Penny Stocks With Promising Potential

Performance Overview